-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NK cells are a promising cancer cell immunotherapy treatment.
cytokine-induced memory sample (ML) NK cells differentiated after being activated by IL-12, IL-15, and IL-18, exhibiting a strong anti-tumor response that can safely induce complete remission in leukemia patients.
, however, many cancers are not yet fully recognized by NK cells.
-embedded antigens (CAR) have been used to enhance tumor-specific identification of effect lymphocytes.
such as Gang and CAR programming can lead to complementary improvements in NK cell response to NK-resistant cancer.
to verify this, the researchers modified the exolytic blood ML NK cells to express anti-CD19 CAR (19-CAR-ML); The specific lethal activity of the modified cells' IFN-ternium synthesis, departitant and anti-NK resistance lymphocyte line and primary target increased significantly, and the reactions of 19-CAR and ML were collaborative, all CAR-specific, and required ITATM signals.
, 19-CAR-ML NK, the source of lymphoma, showed a better response to their own lymphoma.
19-CAR-ML NK cells can control lymphoma load in the body and improve the survival of xygen transplant models.
, the CAR project of ML NK cells enhances the response to drug-resistant cancers and deserves further study, and has the potential to expand the identification of ML NK cells for various NK cell drug-resistant tumors.
.
